|本期目录/Table of Contents|

[1]张莉(综述),杨立勇,沈喜妹(审校).胰高血糖素样肽-1受体激动剂对NAFLD的治疗作用及其抗炎机制[J].福建医科大学学报,2015,49(03):199-202.
点击复制

胰高血糖素样肽-1受体激动剂对NAFLD的治疗作用及其抗炎机制(PDF)
分享到:

《福建医科大学学报》[ISSN:1672-4194/CN:35-1192/R]

卷:
第49卷
期数:
2015年03期
页码:
199-202
栏目:
综述
出版日期:
2015-06-24

文章信息/Info

Title:
-
文章编号:
1672-4194(2015)03-0199-04
作者:
张莉(综述) 杨立勇 沈喜妹(审校)
福建医科大学 附属第一医院内分泌科,福州350005
Author(s):
-
关键词:
胰高血糖素样肽-1 乙醇 脂肪类 肝病 炎症
Keywords:
-
分类号:
R256.4; R341
DOI:
-
文献标志码:
A
摘要:
-
Abstract:
-

参考文献/References:

[1]Tessari P,Coracina A,Cosma A,et al. Hepatic lipid metabolism and non-alcoholic fatty liver disease[J]. Nutr Metab Cardiovasc Dis, 2009,19(4):291-302.
[2]Vernon G,Baranova A,Younossi Z M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults[J]. Alimentary Pharmacology & Therapeutics, 2011,34(3):274-285.
[3]Bourdel-Marchasson I,Schweizer A,Dejager S. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus[J]. Hosp Pract, 2011,39(1):7-21.
[4]Junker A E,Gluud L L,Pedersen J,et al. A 25-year-old woman with type 2 diabetes and liver disease[J]. Case Reports in Gastroenterology, 2014,8(3):398-403.
[5]Pyke C,Heller R S,Kirk R K,et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody[J]. Endocrinology, 2014,155(4):1280-1290.
[6]Ben-Shlomo S,Zvibel I,Shnell M,et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase[J]. Journal of Hepatology, 2011,54(6):1214-1223.
[7]Niu S,Wang L,He M,et al. Exendin-4 regulates redox homeostasis in rats fed with high-fat diet[J]. Acta Biochim Biophys Sin, 2015,47(6):397-403.
[8]Gao H,Zeng Z,Zhang H,et al. The glucagon-like peptide-1 analogue liraglutide inhibits oxidative stress and inflammatory response in the liver of rats with diet-induced non-alcoholic fatty liver disease[J]. Biological & Pharmaceutical Bulletin, 2015,38(5):694.
[9]Plummer M P,Jones K L,Annink C E,et al. Glucagon-like peptide 1 attenuates the acceleration of gastric emptying induced by hypoglycemia in healthy subjects[J]. Diabetes Care, 2014,37(6):1509-1515.
[10]Parlevliet E T,Wang Y,Geerling J J,et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE* 3-Leiden mice[J]. PloS One, 2012,7(11):e49152.
[11]Sharma S,Mells J E,Fu P P,et al. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy[J]. PLoS One, 2011,6(9):e25269.
[12]Hur W,Lee J H,Kim S W,et al. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced pro-inflammatory cytokine production through the AMPK/AKT pathway[J]. Int J Biochem Cell Biol, 2015,64:265-276.
[13]Kodera R,Shikata K,Kataoka H U,et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes[J]. Diabetologia,2011,54(4):965-978.
[14]Lee Y S,Park M S,Choung J S,et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes[J]. Diabetologia, 2012,55(9):2456-2468.
[15]Varanasi A,Patel P,Makdissi A,et al. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors[J]. Endocrine Practice, 2012,18(2):140-145.
[16]Chen H,Simar D,Pegg K,et al. Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal overnutrition in rodents[J]. Diabetologia, 2014,57(3):614-622.
[17]Hirata Y,Kurobe H,Nishio C,et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury[J]. European Journal of Pharmacology, 2013,699(1):106-111.
[18]Daousi C,Pinkney J H,Cleator J,et al. Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state[J]? Regulatory Peptides, 2013,183:54-61.
[19]Parthsarathy V,Hlscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain[J]. European Journal of Pharmacology, 2013,700(1):42-50.
[20]Ojima A,Ishibashi Y,Matsui T,et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression[J]. The American Journal of Pathology, 2013,182(1):132-141.
[21]Baker R G,Hayden M S,Ghosh S. NF-κB, inflammation, and metabolic disease[J]. Cell Metab, 2011,13(1):11-22.
[22]Kodera R,Shikata K,Kataoka H U,et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes[J]. Diabetologia, 2011,54(4):965-978.
[23]Shiraki A,Oyama J,Komoda H,et al. The glucagon-like peptide-1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells[J]. Atherosclerosis, 2012,221:375-382.
[24]Dai Y,Mehta J L,Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation[J]. Cardiovasc Drugs Ther, 2013,27:371-380.
[25]Zhang L,Yang M,Ren H,et al. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK[J]. Liver Int, 2013,33:794-804.

相似文献/References:

[1]何保昌,陈 法,蔡 琳.饮酒、吸烟及其交互作用与口腔癌关系的病例对照研究[J].福建医科大学学报,2014,48(01):42.
 HE Baochang,CHEN Fa,CAI Lin.The Case-control Study of the Relationship betweenAlcohol Drinking, Tobacco Smoking and Oral Cancer[J].Journal of Fujian Medical University,2014,48(03):42.

备注/Memo

备注/Memo:
收稿日期: 2015-04-17
基金项目: 国家自然科学基金(81370912)
作者单位: 福建医科大学 附属第一医院内分泌科,福州350005
作者简介: 张莉(1989-),女,福建医科大学2013级硕士研究生. Email: 491454039@qq.com
更新日期/Last Update: 2015-09-30